Cerenis Therapeutics Aktie

NeuKaufen Kaufen Verkaufen Verkaufen

1,17 EUR -0,01 EUR -0,68 %

23.12.2024

STU

1,21 EUR -0,03 EUR -2,26 %

23.12.2024

PAR

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.41,96 Mio. EUR

Div. Rendite0,00%

WKNA14QR9

ISINFR0012616852

Cerenis Therapeutics Aktien News

Sortieren:Datum Meistgelesen

13.06.24BusinesswireABIONYX Pharma has completed a successful pre-IND meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis

15.02.24BusinesswireABIONYX Pharma Acknowledges the Clinical Results of the Phase 3 AEGIS-II Study Evaluating the Efficacy and Safety of CSL Behring’s Human-plasma-derived apoA-I, CSL112

02.11.23BusinesswireABIONYX Pharma RACERS Study Data in Sepsis Presented at the American Society of Nephrology (ASN) 2023 Annual Meeting "Kidney Week"

WerbungCerenis Therapeutics-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

16.10.23BusinesswireABIONYX Pharma RACERS Study in Sepsis Selected for Late-Breaking Clinical Results Poster Presentation at the American Society of Nephrology (ASN) 2023 Annual Meeting "Kidney Week"

31.03.23BusinesswireABIONYX Pharma Announces Its Strategy in Ophthalmology and New Positive Preclinical Results for the Deployment of Two Innovative Technology Platforms: Apotherapy and Biovectorization

16.01.23BusinesswireABIONYX Pharma Reports Positive Results from Phase 2a Pilot Clinical Trial Evaluating CER-001 in the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury

07.04.22BusinesswireABIONYX Pharma Reports Positive Interim Results From Phase 2a Clinical Trial Evaluating CER-001 in the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury

29.03.22BusinesswireABIONYX Pharma Receives FDA Orphan Drug Designation (ODD) for CER-001 for the Treatment of LCAT Deficiency Presenting as Kidney Dysfunction and/or Ophthalmologic Disease

24.03.22BusinesswireABIONYX Announces Positive Clinical Findings for CER-001 in Treating COVID-19, Published in Biomedecines, Demonstrating That CER-001 Limits Inflammation Effects

Cerenis Therapeutics News

Cerenis Therapeutics News: auf dieser Seite finden Sie alle Cerenis Therapeutics News und Nachrichten zur Cerenis Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Cerenis Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Cerenis Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.